Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing
Rhea-AI Summary
Ainos, Inc. (NASDAQ:AIMD) has secured exclusive licenses for 10 invention patents and patent applications from Taiwan Carbon Nano Technology (TCNT), its affiliate and product co-developer. The licenses, valued at approximately $5.4 million, cover gas sensors and medical devices across multiple regions including the U.S., Germany, China, Japan, and Taiwan. The all-stock licensing structure aligns TCNT's interests with Ainos shareholders while preserving cash for growth.
This strategic move is expected to strengthen Ainos' AI Nose and Point-Of-Care Testing (POCT) technologies. The company is advancing its AI Nose and POCT pipeline, including the leading volatile organic compounds (VOC) POCT candidate, Ainos Flora. Ainos is also developing a VOC sensing platform with Japanese partners and progressing on the Next-Gen Ainos Flora, which implements NVIDIA CUDA technology.
Positive
- Secured exclusive licenses for 10 invention patents and patent applications
- All-stock licensing structure preserves cash for growth
- Strengthens AI Nose and POCT technologies
- Advancing VOC POCT candidate Ainos Flora
- Developing VOC sensing platform with Japanese partners
- Progressing on Next-Gen Ainos Flora with NVIDIA CUDA implementation
Negative
- Issuance of shares worth $5.4 million may lead to dilution for existing shareholders
Insights
This patent licensing deal is a strategic move for Ainos, significantly strengthening their intellectual property portfolio in AI-powered point-of-care testing (POCT) and gas sensor technology. The acquisition of 10 invention patents and applications across multiple regions, including key markets like the U.S., Germany and China, provides Ainos with a competitive edge in the rapidly evolving medical device sector.
The focus on volatile organic compounds (VOC) sensing technology, particularly for their Ainos Flora product, positions the company at the forefront of non-invasive diagnostic solutions. The integration of NVIDIA CUDA for the Next-Gen Ainos Flora suggests a push towards more powerful AI processing capabilities, potentially enabling faster and more accurate diagnostics. This could be a game-changer in the POCT market, offering quicker results and improved patient care.
The all-stock transaction structure for this patent licensing deal is financially prudent. By issuing shares valued at approximately
However, investors should note the dilutive effect of this stock issuance on existing shareholders. The deal's true value will depend on Ainos's ability to monetize these patents effectively through product development and market penetration. The company's focus on AI-powered POCT and VOC sensing could tap into the growing demand for rapid, non-invasive diagnostics, potentially driving future revenue growth if successfully commercialized.
Exclusive licensing of 10 invention patents and patent applications surrounding gas sensor and medical devices
All-stock licensing structure aligns the licensor's long-term interest with Ainos shareholders'
SAN DIEGO, CA / ACCESSWIRE / August 9, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA low-dose interferon therapeutics, today announced that it has obtained exclusive licenses for a total of 10 invention patents and patent applications from Taiwan Carbon Nano Technology ("TCNT"), the Company's affiliate and product co-developer.
TCNT agreed to assign and grant exclusive, irrevocable, and perpetual licenses of 10 invention patents and patent applications related to gas sensors and medical devices in exchange for the Company's shares of common stock with a total value of approximately US
"I believe this licensing will bolster our AI Nose and POCT technologies as we advance our AI Nose and POCT pipeline, including progressing our leading volatile organic compounds ("VOC") POCT candidate, Ainos Flora, and jointly developing a VOC sensing platform with our Japanese partners. We are also moving forward with the Next-Gen Ainos Flora with an implementation of NVIDIA CUDA, targeting Q3 for design completion and Q4 for clinical trial kickoff. This all-stock licensing structure aligns TCNT's interest with Ainos shareholders' while preserving cash for our growth," Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented.
About Ainos, Inc.
Headquartered in San Diego, California, Ainos is a diversified healthcare company focused on novel AI-powered point-of-care testing (POCT) and low-dose interferon therapeutics (VELDONA). The Company's clinical-stage product pipeline includes VELDONA human and animal oral therapeutics, human orphan drugs, and telehealth-friendly POCT solutions powered by its AI Nose technology platform.
The name "Ainos" is a combination of "AI" and "Nose" to reflect the Company's commitment to empowering individuals to manage their health more effectively with next-generation AI-driven POCT solutions. To learn more, visit https://www.ainos.com.
Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Safe Harbor Statement
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements can be identified by the use of words such as "anticipate," "believe," "estimate," "approximate," "expect," "intend," "plan," "predict," "project," "target," "future," "likely," "strategy," "foresee," "may," "guidance," "potential," "outlook," "forecast," "should," "will" or other similar words or phrases. Similarly, statements that describe the Company's objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements are based only on the Company's current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. The Company's actual results may differ materially from those indicated in the forward-looking statements.
Important factors that could cause the Company's actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release include, among others, the cost of production and sales potential of the products announced in this press release; the Company's dependence on projected revenues from the sale of current or future products ; the Company's limited cash and history of losses; the Company's ability to achieve profitability; the Company's ability to raise additional capital to continue the Company's product development; the ability to accurately predict the future operating results of the Company; the ability to advance Ainos' current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates the Company develops; the ability to obtain and maintain regulatory approval of Ainos' product candidates; delays in completing the development and commercialization of the Company's current and future product candidates, which could result in increased costs to the Company, delay or limit the ability to generate revenue and adversely affect the business, financial condition, results of operations and prospects of the Company; intense competition and rapidly advancing technology in the Company's industry that may outpace its technology; customer demand for the products and services the Company develops; the accuracy of third-party market research data, the impact of competitive or alternative products, technologies and pricing; disruption in research and development facilities; lawsuits and other claims by third parties or investigations by various regulatory agencies governing the Company's operations; potential cybersecurity attacks; increased requirements and costs related to cybersecurity; the Company's ability to realize the benefits of third party licensing agreements; the Company's ability to obtain and maintain intellectual property protection for Ainos product candidates; compliance with applicable laws, regulations and tariffs; continued listing on and compliance with the applicable regulations of the Nasdaq Capital Market; and the Company's success in managing growth. A more complete description of these risk factors and others is included in the "Risk Factors" section of Ainos' Annual Report on Form 10-K for the year ended December 31, 2023, and other public filings with the U.S. Securities and Exchange Commission ("SEC"), many of which risks are beyond the Company's control. In addition to the risks described above and in the Company's filings with the SEC, other unknown or unpredictable factors also could cause actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release.
The forward-looking statements made in this press release are expressly qualified in their entirety by the foregoing cautionary statements. Any forward-looking statements contained in this press release represent Ainos' views only as of today and should not be relied upon as representing its views as of any subsequent date. Ainos undertakes no obligation to, and expressly disclaims any such obligation to, publicly update or revise any forward-looking statement to reflect changed assumptions, the occurrence of anticipated or unanticipated events or changes to the future results over time or otherwise, except as required by law.
Investor Relations Contact
Feifei Shen
Email: IR@ainos.com
SOURCE: Ainos, Inc.
View the original press release on accesswire.com
FAQ
What patents did Ainos (AIMD) acquire in August 2024?
How much did Ainos (AIMD) pay for the patent licenses?
What regions are covered by the patents Ainos (AIMD) licensed?
How will these patents benefit Ainos' (AIMD) technology development?
